Page last updated: 2024-12-05

2,6-diethylaniline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,6-Diethylaniline is an organic compound with the formula C10H15N. It is a colorless liquid that is used as an intermediate in the synthesis of dyes, pharmaceuticals, and other organic compounds. The compound is typically synthesized via the reduction of 2,6-dinitroethylbenzene using either catalytic hydrogenation or iron in acidic conditions. 2,6-Diethylaniline is an important intermediate in the synthesis of several drugs including antimalarials, antiseptics, and local anesthetics. The compound is also studied for its potential application in the synthesis of novel organic materials, such as conducting polymers.'

2,6-diethylaniline: one of the major metabolites of the herbicide alachlor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11369
CHEMBL ID3184218
SCHEMBL ID262868
MeSH IDM0227362

Synonyms (58)

Synonym
4-12-00-02841 (beilstein handbook reference)
vt2234594h ,
unii-vt2234594h
2,6-diethyl aniline
benzamine, 2,6-diethyl-
ai3-26297
brn 1423626
hsdb 5699
einecs 209-445-7
ccris 2688
2,6-diethylbenzenamine
benzenamine, 2,6-diethyl-
aniline, 2,6-diethyl-
2,6-diethylaniline
579-66-8
inchi=1/c10h15n/c1-3-8-6-5-7-9(4-2)10(8)11/h5-7h,3-4,11h2,1-2h
2,6-diethylaniline, 98%
D0476
diethylaminobenzene
2-amino-1,3-diethylbenzene
2,6 diethylaniline
AKOS000120339
A831688
NCGC00247995-02
NCGC00247995-01
(2,6-diethyl-phenyl)-amine
2,6-diethyl-aniline
dtxsid6027218 ,
tox21_202010
dtxcid607218
NCGC00259559-01
cas-579-66-8
tox21_300333
NCGC00254454-01
2,6-diethylphenylamine
FT-0610638
2,6-diethylaniline [hsdb]
SCHEMBL262868
2.6-diethylaniline
4-iodopyridine-2,6-dicarboxylicacid
W-105426
CHEMBL3184218
mfcd00007753
AC-10108
2,6-diethylaniline, >=99.5%
2,6-diethylaniline, pestanal(r), analytical standard
2,6-diethyl-benzenamine
2,6-diethyl-benzamine
2,6-diethylbenzenamine, 9ci
CS-W018171
F0001-1508
STL570693
DS-13621
Q209276
AM10640
D77824
EN300-20612
Z104479240

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" ANOVA analyses indicated that there is a dose-response relationship between doses of N,N-diethylaniline and the frequency of SCEs, especially in the presence of S-9 mix."( Sister chromatid exchanges of human peripheral blood lymphocytes induced by N,N-diethylaniline in vitro.
Li, Q; Minami, M, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
butachlor degradation013

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency33.86260.000229.305416,493.5996AID743075
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency61.90010.000323.4451159.6830AID743065; AID743067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (45.45)18.2507
2000's3 (27.27)29.6817
2010's3 (27.27)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.19 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index37.47 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]